Screening for cognitive sequelae of SARS-CoV-2 infection: a comparison between the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA).
COVID-19
Cognitive screening
Mini-Mental State Examination
Montreal Cognitive Assessment
Psychometrics
SARS-CoV-2
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
02
09
2021
accepted:
22
09
2021
pubmed:
21
10
2021
medline:
6
1
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
Due to SARS-CoV-2-related encephalopathic features, COVID-19 patients may show cognitive sequelae that negatively affect functional outcomes. However, although cognitive screening has been recommended in recovered individuals, little is known about which instruments are suitable to this scope by also accounting for clinical status. This study thus aimed at comparatively assessing the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) in detecting cognitive deficits in post-COVID-19 patients premorbidly/contextually being or not at risk for cognitive deficits (RCD + ; RCD-). Data from N = 100 COVID-19-recovered individuals having been administered both the MMSE and the MoCA were retrospectively analyzed separately for each group. RCD ± classification was performed by taking into consideration both previous and disease-related conditions. Equivalent scores (ESs) were adopted to examine classification performances of the two screeners. The two groups were comparable as for most background and cognitive measures. MMSE or MoCA adjusted scores were mostly unrelated to disease-related features. The two screeners yielded similar estimates of below-cut-off performances-RCD + : MMSE: 20%, MoCA: 23.6%; RCD-: MMSE: 2.2%, MoCA: 4.4%. However, agreement rates dropped when also addressing borderline, "low-end" normal, and normal ability categories-with the MoCA attributing lower levels than the MMSE (RCD + : Cohen's k = .47; RCD-: Cohen's k = .17). Although both the MMSE and the MoCA proved to be equally able to detect severe cognitive sequelae of SARS-CoV-2 infection in both RCD + and RCD- patients, the MoCA appeared to be able to reveal sub-clinical defects and more sharply discriminate between different levels of ability.
Sections du résumé
BACKGROUND
BACKGROUND
Due to SARS-CoV-2-related encephalopathic features, COVID-19 patients may show cognitive sequelae that negatively affect functional outcomes. However, although cognitive screening has been recommended in recovered individuals, little is known about which instruments are suitable to this scope by also accounting for clinical status. This study thus aimed at comparatively assessing the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) in detecting cognitive deficits in post-COVID-19 patients premorbidly/contextually being or not at risk for cognitive deficits (RCD + ; RCD-).
METHODS
METHODS
Data from N = 100 COVID-19-recovered individuals having been administered both the MMSE and the MoCA were retrospectively analyzed separately for each group. RCD ± classification was performed by taking into consideration both previous and disease-related conditions. Equivalent scores (ESs) were adopted to examine classification performances of the two screeners.
RESULTS
RESULTS
The two groups were comparable as for most background and cognitive measures. MMSE or MoCA adjusted scores were mostly unrelated to disease-related features. The two screeners yielded similar estimates of below-cut-off performances-RCD + : MMSE: 20%, MoCA: 23.6%; RCD-: MMSE: 2.2%, MoCA: 4.4%. However, agreement rates dropped when also addressing borderline, "low-end" normal, and normal ability categories-with the MoCA attributing lower levels than the MMSE (RCD + : Cohen's k = .47; RCD-: Cohen's k = .17).
DISCUSSION
CONCLUSIONS
Although both the MMSE and the MoCA proved to be equally able to detect severe cognitive sequelae of SARS-CoV-2 infection in both RCD + and RCD- patients, the MoCA appeared to be able to reveal sub-clinical defects and more sharply discriminate between different levels of ability.
Identifiants
pubmed: 34668124
doi: 10.1007/s10072-021-05630-3
pii: 10.1007/s10072-021-05630-3
pmc: PMC8526352
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
81-84Informations de copyright
© 2021. Fondazione Società Italiana di Neurologia.
Références
Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T (2020) Neurological associations of COVID-19. The Lancet Neurology 19:767–783
Daroische R, Hemminghyth MS, Eilertsen TH, Breitve MH, Chwiszczuk LJ (2021) Cognitive impairment after COVID-19 - a review on objective test data. Front Neurol 12:1238
doi: 10.3389/fneur.2021.699582
Wilson BA, Betteridge S, Fish J (2020) Neuropsychological consequences of COVID-19. Neuropsychol Rehabil 30:1625–1628
doi: 10.1080/09602011.2020.1808483
Pistarini C, Fiabane E, Houdayer E, Vassallo C, Manera MR, Alemanno F (2021) Cognitive and emotional disturbances due to COVID-19: an exploratory study in the rehabilitation setting. Front Neurol 12:643646
doi: 10.3389/fneur.2021.643646
Capitani E, Laiacona M (2017) Outer and inner tolerance limits: their usefulness for the construction of norms and the standardization of neuropsychological tests. Clin Neuropsychol 31:1219–1230
doi: 10.1080/13854046.2017.1334830
Aiello EN, Gramegna C, Esposito A, Gazzaniga V, Zago S, Difonzo T, Maddaluno O, Appollonio I, Bolognini N (2021) The Montreal Cognitive Assessment (MoCA): updated norms and psychometric insights into adaptive testing from healthy individuals in Northern Italy. Aging Clin Exp Res 1–8. https://doi.org/10.1007/s40520-021-01943-7
Carpinelli Mazzi M, Iavarone A, Russo G, Musella C, Milan G, D’Anna F, Garofalo E, Chieffi S, Sannino M, Illario M, De Luca V (2020) Mini-Mental State Examination: new normative values on subjects in Southern Italy. Aging Clin Exp Res 32:699–702
doi: 10.1007/s40520-019-01250-2
Sim J, Wright CC (2005) The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 85:257–268
doi: 10.1093/ptj/85.3.257
Blazhenets G, Schröter N, Bormann T, Thurow J, Wagner D, Frings L, Weiller C, Meyer PT, Dressing A, Hosp JA (2021) Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med 62(7):910–915
doi: 10.2967/jnumed.121.262128
Miskowiak KW, Johnsen S, Sattler SM, Nielsen S, Kunalan K, Rungby J, Lapperre T, Porsberg CM (2021) Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol 46:39–48
doi: 10.1016/j.euroneuro.2021.03.019